Core Scientific, Inc./tx 8-K

What Happened
Core Scientific, Inc. (CORZ) announced a proposed private offering of $3.3 billion aggregate principal amount of senior secured notes due 2031. The notes would be issued by Core Scientific Finance I LLC, an indirect subsidiary, and offered to qualified institutional buyers under Rule 144A and to non‑U.S. persons under Regulation S. The notes will be guaranteed by five subsidiary entities (Core Scientific Austin LLC, Denton LLC, Dalton LLC, Marble LLC and Muskogee LLC); the parent company is not issuing securities or guaranteeing the notes. Core Scientific stated the issuer intends to use a substantial portion of the net proceeds to pay a distribution to the company, which the company intends to use in part to repay in full its outstanding delayed-draw term loans under the Delayed-Draw Bridge Credit Agreement (dated March 4, 2026; amended March 18, 2026). The company announced the commencement of the offering in a press release on April 21, 2026.

Key Details

• Proposed aggregate principal amount: $3.3 billion; maturity: 2031.
• Issuer: Core Scientific Finance I LLC (indirect subsidiary); Subsidiary guarantors: Core Scientific Austin, Denton, Dalton, Marble and Muskogee LLCs.
• Offering type: private placement to QIBs (Rule 144A) and to non‑U.S. persons (Regulation S).
• Use of proceeds: substantial portion to fund a distribution to the parent; parent will use part of that distribution to repay delayed‑draw term loans in full under the March 4, 2026 bridge facility (amended Mar 18, 2026). Press release and supplemental info were furnished with the 8‑K (filed April 21, 2026).

Why It Matters
This filing shows the company pursuing a large debt issuance at the subsidiary level and planning to use proceeds to eliminate the parent’s outstanding delayed‑draw bridge loans. Investors should note that the parent company is not guaranteeing the new notes while the subsidiary issuers and five subsidiaries will guarantee them, and that the transaction is being conducted as a private placement limited to institutional and non‑U.S. investors. Review the company’s press release and the supplemental materials (Exhibits 99.1 and 99.2) for more detail on timing, terms and potential impact on Core Scientific’s capital structure.